Top Feed
Ipsen strikes €1bn deal to acquire French biotech ImCheck Therapeutics
New Continuation Fee Among 2025 USPTO Changes Impacting Biotech
Neuphoria, reeling from phase 3 trial fail, mulls buyout offer from investor
Can Oncolytics Biotech Inc. stock rebound after recent weakness - Market Weekly Review & Long-Term Safe Investment Plans
Why Trinity Biotech plc Depositary Receipt is moving today - Market Sentiment Review & Community Trade Idea Sharing
The biotech mapping thousands of hidden therapeutic clues
BIS closes probe into US biotech company
Big Pharma-backed Rome Therapeutics nears end of road with planned layoffs and strategic review
Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
Biotech & Pharma Q2 2025: AI Innovations, M&A Moves, and Policy Challenges Unveiled
Biotech and pharma market forecast for 2025. The biotech and pharma sectors entered Q4 on firm footing. Supportive market dynamics are expected...
Ipsen strikes €1bn deal to acquire French biotech ImCheck Therapeutics
The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia.
New Continuation Fee Among 2025 USPTO Changes Impacting Biotech
USPTO's new Continuation Application Fee may jeopardize biotech priority claims. Learn how delayed filings could silently lose rights under...
Neuphoria, reeling from phase 3 trial fail, mulls buyout offer from investor
As Neuphoria considers its options in the wake of the failure of it social anxiety program, an investor has swooped in with one potential...
Can Oncolytics Biotech Inc. stock rebound after recent weakness - Market Weekly Review & Long-Term Safe Investment Plans
【Stock Group】✌️ Free US stock market updates and professional advice help you discover high-return stocks with over 200% gains and...
Why Trinity Biotech plc Depositary Receipt is moving today - Market Sentiment Review & Community Trade Idea Sharing
【Stock Picks】✌️ Our free US stock group shares handpicked, low-risk stocks with proven 200%+ returns to empower your portfolio with high...
The biotech mapping thousands of hidden therapeutic clues
Tens of thousands of previously unknown proteins, hiding in plain sight, may hold the key to a new generation of precision medicines.
BIS closes probe into US biotech company
Pacific Biosciences of California said the export enforcer issued the company a warning letter without penalties after inquiring about a...
Big Pharma-backed Rome Therapeutics nears end of road with planned layoffs and strategic review
Rome's pipeline is built on twin franchises, one composed of reverse transcriptase inhibitors and another pursuing tumor antigens. The closest...
Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the...
Biotech Review
@BiotechReview
2113
Stats
67300
Rank
2.1K
Points
0
Videos
14
Articles
0
Reviews
0
Comments
Profile
Groups
This member is not part of any groups yet.